Cytokinetics reports positive Phase 3 ACACIA-HCM results; plans FDA sNDA in Q4 2026
Cytokinetics says Phase 3 ACACIA-HCM results are positive and it plans to file an FDA sNDA in Q4 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.